| Literature DB >> 28710827 |
Won Hee Lee1,2, Wen-Yi Chen1,2, Ning-Yi Shao1,2, Dan Xiao1,2, Xulei Qin1,2, Natalie Baker1,2, Hye Ryeong Bae1,2, Tzu-Tang Wei1,2, Yongjun Wang1,2, Praveen Shukla1,2, Haodi Wu1,2, Kazuki Kodo1,2, Sang-Ging Ong1,2, Joseph C Wu1,2,3.
Abstract
Both human embryonic stem cell-derived cardiomyocytes (ESC-CMs) and human induced pluripotent stem cell-derived CMs (iPSC-CMs) can serve as unlimited cell sources for cardiac regenerative therapy. However, the functional equivalency between human ESC-CMs and iPSC-CMs for cardiac regenerative therapy has not been demonstrated. Here, we performed a head-to-head comparison of ESC-CMs and iPSC-CMs in their ability to restore cardiac function in a rat myocardial infarction (MI) model as well as their exosomal secretome. Human ESCs and iPSCs were differentiated into CMs using small molecule inhibitors. Fluorescence-activated cell sorting analysis confirmed ∼85% and ∼83% of CMs differentiated from ESCs and iPSCs, respectively, were positive for cardiac troponin T. At a single-cell level, both cell types displayed similar calcium handling and electrophysiological properties, with gene expression comparable with the human fetal heart marked by striated sarcomeres. Sub-acute transplantation of ESC-CMs and iPSC-CMs into nude rats post-MI improved cardiac function, which was associated with increased expression of angiogenic genes in vitro following hypoxia. Profiling of exosomal microRNAs (miRs) and long non-coding RNAs (lncRNAs) revealed that both groups contain an identical repertoire of miRs and lncRNAs, including some that are known to be cardioprotective. We demonstrate that both ESC-CMs and iPSC-CMs can facilitate comparable cardiac repair. This is advantageous because, unlike allogeneic ESC-CMs used in therapy, autologous iPSC-CMs could potentially avoid immune rejection when used for cardiac cell transplantation in the future. Stem Cells 2017;35:2138-2149.Entities:
Keywords: Cell therapy; Embryonic stem cell-derived cardiomyocyte; Exosomes; Induced pluripotent stem cell-derived cardiomyocyte; Stem cells
Mesh:
Year: 2017 PMID: 28710827 PMCID: PMC5918285 DOI: 10.1002/stem.2669
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277